Exelixis, Inc. - Common Stock (NQ:EXEL)

58.34 -0.05 (-0.09%)

Delayed Quote Updated: 9:57 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday ↗

June 23, 2025

Via Benzinga

Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug ↗

June 23, 2025

Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.

Via Investor's Business Daily

What 9 Analyst Ratings Have To Say About Exelixis ↗

June 23, 2025

Via Benzinga

These stocks are moving in today's pre-market session ↗

June 23, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

Analyst Expectations For Exelixis's Future ↗

June 05, 2025

Via Benzinga

Price Over Earnings Overview: Exelixis ↗

May 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 23, 2025

Via Benzinga

Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket ↗

June 23, 2025

Via Benzinga

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

June 22, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

June 20, 2025

From Exelixis, Inc.

Via Business Wire

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors ↗

June 17, 2025

EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation ↗

June 13, 2025

EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.

Via Chartmill

DoorDash To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗

June 12, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Undervalued Biotech Stocks ↗

June 10, 2025

EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, growth, and financial health, making it a compelling pick for value investors.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup ↗

June 06, 2025

EXELIXIS INC (NASDAQ:EXEL) combines strong earnings momentum with a high technical rating, making it a standout for growth investors. The stock's breakout setup suggests potential upside.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential ↗

June 03, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities.

Via Chartmill

2 Top Stocks to Buy With Less Than $100 ↗

May 30, 2025

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors ↗

May 26, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.

Via Chartmill

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

May 22, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

May 22, 2025

From Exelixis, Inc.

Via Business Wire

EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation ↗

May 22, 2025

EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – An Undervalued Biotech Stock with Strong Fundamentals ↗

May 20, 2025

EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.

Via Chartmill

CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio? ↗

May 18, 2025

Large-cap stocks surged in the last week. CoreWeave, Super Micro, Coinbase, NRG Energy, Astera Labs, First Solar, Exelixis, Rocket Lab, Hims & Hers, On Holding and Gap were the top performers.

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High Growth Momentum and Minervini’s Trend Template ↗

May 17, 2025

EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before...

Via Chartmill

9 Health Care Stocks With Whale Alerts In Today's Session ↗

May 16, 2025

Via Benzinga

Demystifying Exelixis: Insights From 8 Analyst Reviews ↗

May 15, 2025

Via Benzinga

Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat ↗

May 14, 2025

Exelixis lifts 2025 revenue outlook after strong Q1 driven by Cabometyx sales surge and early traction in the neuroendocrine tumor market.

Via Benzinga

Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday? ↗

May 14, 2025

Nasdaq 100 rises further as Nvidia and AMD rally on Middle East investment hopes, while gold tumbles and Treasury yields surge.

Via Benzinga

Why Exelixis Stock Is Skyrocketing Today ↗

May 14, 2025

Via The Motley Fool

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance ↗

May 14, 2025

Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.